Introduction
Cytotoxic drugs include any drug that inhibits or prevents the function of cells. Cytotoxic drugs include drugs used to treat cancer and in some cases, to treat certain skin conditions (e.g., psoriasis). This guide explains the duty of an employer in a health care facility to protect workers who are likely to be exposed to cytotoxic drugs. Such worker exposure may occur at health care facilities such as hospitals, Special Care and Personal Care Homes, cancer and other medical clinics, and in home care situations.
Reasons for concern
There has been a considerable increase in concern over the potential of cytotoxic drugs to harm workers who are likely to be exposed to them. This includes workers who prepare, administer, or handle the drugs. The concern is based on:
• toxic side effects seen in patients treated with these drugs
• evidence that these drugs can produce chromosome changes, cancer, and reproductive abnormalities in animal experiments
• adverse effects in workers exposed to them When therapeutic doses are given to patients, cytotoxic drugs produce toxic side effects due to their poor selectivity between target (e.g., cancer cells) and normal cells.
There is ample evidence that many of these drugs cause serious adverse effects in cancer patients receiving long-term therapy. These adverse effects include:
• neoplasms and leukemias
• testicular and ovarian dysfunction -including permanent sterility
• cumulative chromosome damage
• other organ damage
Animal studies confirm the potential of these agents to induce malignancy and to cause chromosomal damage and reproductive abnormalities. Appendix 1 lists antineoplastic or anti-cancer drugs that
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have been classified by the International Agency for Research on Cancer (IARC) as possible or probable cancer-causing agents. Not all cytotoxic drugs are carcinogenic. In particular, antimetabolites such as methotrexate (amethopterin), cytarabine (cytosar), and 5-fluorouracil (5-FU) have not caused cancer in animal studies or in humans receiving therapeutic treatments, despite their use by a large number of patients over many years. On the other hand, the alkylating agents (in particular nitrogen mustards, ethylenimine derivatives, and nitrosoureas) have been shown repeatedly to be carcinogenic in laboratory systems and in cancer patients. Studies of worker exposure to cytotoxic drugs have shown:
• detectable levels of cytotoxic drugs in the air of hospital areas where parenteral cytotoxic drugs are prepared without the use of biological safety cabinets (BSC)
• detectable amounts of various cytotoxic drugs in the urine of health care workers preparing the drugs without adequate precautions
There is also evidence that exposure to cytotoxic drugs can cause adverse effects in workers. There are reports that exposure to cytotoxic drugs:
• can cause an increased frequency of chromosome damage in exposed workers
• can produce some acute effects in workers which include skin, eyes, and mucous membrane irritations, allergic reactions upon contact with the skin, as well as subjective symptoms including nausea, headache, and dizziness
• has been associated with adverse reproductive outcomes (including higher incidences of spontaneous abortions and a higher risk of delivering malformed babies)
Repeated, long term occupational exposure to small amounts of cytotoxic drugs has not been identified as a cause of cancer. However, because of the above mentioned concerns, precautions must be followed to limit occupational exposure to all cytotoxic drugs.
Sources of exposure
Worker exposure occurs by inhalation of drug dust or aerosol, absorption through the skin, and ingestion through contact with contaminated food, drink, or cigarettes. The aerosol is generated during the preparation or the administration of the drug, (e.g., while breaking open ampules, withdrawing needles from drug vials, transferring drugs with syringes, or expelling air from a drug-filled syringe). Such aerosol can result in exposing not only the worker immediately involved, but also exposing other people in the surrounding areas. Workers may also be exposed to cytotoxic drugs when they handle contaminated equipment and supplies.
Responsibilities for controlling exposure
Section 471 of The Occupational Health and Safety Regulations, 1996 , requires employers in health care facilities to take all practicable steps to minimize worker exposure to cytotoxic drugs or materials, or equipment contaminated with cytotoxic drugs. Where workers are required to prepare, administer, handle, or use cytotoxic drugs or are likely to be exposed to them, the employer must prepare and implement a written program. The program includes written procedures and other precautions to ensure the health and safety of workers. The employer must train workers on the content of the program and its procedures when implementing the program. Where workers prepare parenteral cytotoxic drugs on a frequent and continuing basis, the employer must provide and maintain an approved biological safety cabinet (BSC) and ensure it is used safely. The regulations also place duties on workers to co-operate with the employer and use the safe work procedures and protective equipment referred to in the written program.
Guidelines for controlling exposures
The following guidelines explain the employer's duties under section 471 of the regulations and are intended to assist the employer in developing the written program.
The written program
The occupational health committee must be consulted in developing the written program. The program must address the following issues: 1 How cytotoxic drugs, supplies, and equipment contaminated with cytotoxic drugs will be: 2 Emergency procedures to use: a) when a cytotoxic drug spills or leaks, (e.g., from a damaged package) or b) when a worker is exposed to cytotoxic drugs as a result of:
• a skin puncture
• contact with intact skin
• contact with the eye
• accidental inhalation of drug dust or aerosol, or
• swallowing a substance contaminated with a cytotoxic drug 3 How equipment that becomes contaminated with cytotoxic drugs will be maintained or disposed of.
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4 The use of: a) engineering controls (e.g., general or local exhaust ventilation) b) work practices c) hygiene practices (e.g., personal hygiene standards). These standards should include a ban on eating, drinking, smoking, applying cosmetics, or storing food in or near the preparation area d) hygiene facilities (such as personal wash facilities) e) approved respiratory protective devices, approved eye or face protectors, and other appropriate personal protective equipment f) decontamination materials and equipment that are appropriate in the circumstances 5 The use of an approved BSC for preparing cytotoxic drugs and methods of maintaining the cabinet.
Once prepared, the program must be implemented. Workers must be trained on the program and a copy of the program must be made available to them for their reference.
The following sections describe protective measures to minimize workers' exposure.
Preparation of parenteral cytotoxic drugs
Before preparing the written program, determine whether the facility will be equipped to prepare parenteral cytotoxic drugs.
The employer must make a determination of whether the health care facility will prepare parenteral cytotoxic drugs on a frequent and continuing basis. To make this determination, the employer needs to examine the present situation at the facility considering the size of the population being served, the size of the facility, how frequently parenteral cytotoxic drugs have been prepared in the past, and the location of the nearest facility that has an approved BSC. The employer should also consider any intended changes to the current situation. For example, are there any intended changes in the size of the population being served or other reasons that might increase the frequency of cytotoxic (parenteral) drug preparations? Where the determination is made that parenteral cytotoxic drugs will be prepared on a frequent and continuing basis in the facility, an approved BSC must be provided to workers. Where this is not the case, the employer must make this intention clear to the occupational health committee and the workers, and should also explain to clients what the alternate arrangements are. An alternative arrangement may be made with another facility. These drugs could be prepared at a nearby facility that has an approved BSC and then transported to the facility where the drugs will be administered to patients. Other alternatives should also be considered. For example, the patient may travel to another nearby health care facility that is suitably equipped to prepare parenteral cytotoxic drugs. Parenteral cytotoxic drugs may be prepared on an occasional or interim basis at a health care facility that does not have an approved BSC, where:
• exceptional circumstances arise
• alternative arrangements prove impractical to use, or
• the employer has planned for, but not yet received, the BSC In such cases, the employer must determine what arrangements can be made in the facility to minimize worker exposure to parenteral cytotoxic drugs being prepared. The arrangement must include measures to protect the worker preparing the drug, other workers in the vicinity, and prevent the spread of drug contamination from the immediate vicinity of the preparation area. 
Approved Biological Safety Cabinets (BSC)

Using and maintaining the Biological Safety Cabinet
The BSC must be inspected and certified by a competent person at least annually and when the cabinet is moved. See the Resources section for example agencies that provide this service in the province. The BSC must be cleaned, maintained, and used according to the manufacturer's recommendations. The exhaust blower on the BSC should be operated continuously -even when not in use. The cabinet should be cleaned daily with 70 percent alcohol and decontaminated weekly or whenever spills occur. Decontamination should consist of surface cleaning with an alkaline detergent followed by thorough rinsing. Personal protective equipment as described later in this document should be used while decontaminating the cabinet. The ductwork attached to the cabinet should be labelled as to its hazardous content.
Where the Biological Safety Cabinet is not required
A centralized area for the preparation of cytotoxic drugs should be designated. The area should be a work area that is quiet, uncluttered, and well ventilated. The ventilation system, fans or air conditioning unit should not blow air directly at the preparation area. The area should be clearly posted with a sign identifying it as a cytotoxic drug preparation area.
Respiratory protection
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Approved respiratory protection must be provided by the employer and worn by workers who may be exposed to cytotoxic drug dusts or aerosols. This type of exposure may occur when workers:
• prepare cytotoxic drugs on a counter or some other place that is outside of an approved BSC
• clean up spilled cytotoxic drugs
• decontaminate a BSC that has the sash raised
Approved respiratory devices
Approved respiratory protective devices include a reusable facemask with filter cartridges, or a disposable filter mask. The filter cartridges or the filter mask must provide high efficiency particulate air (HEPA) filtration and carry the National Institute for Occupational Safety and Health (NIOSH) label with either the N100, P100, or R100 rating.
These respirators are available from most safety equipment suppliers. Surgical masks are neither suitable nor adequate to protect the worker.
Use and maintenance of respirators
Workers should be trained to use their respirator properly. Training should include how to ensure a proper fit and prevent the contamination of the inner surface of the respirator. Reusable facemasks should be cleaned and inspected after each day's use. The cartridge should be replaced according to manufacturer's recommendations. When not in use, respirators should be stored in a dust-proof, sanitary location.
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Other personal protective equipment
Personal protective equipment should be provided for and used by workers preparing or administering the drugs. The equipment should include well-fitted disposable gloves, an appropriate protective gown, and eye protection.
Gloves
Thicker gloves provide better protection, as cytotoxic drugs can permeate most glove materials -including latex. Non-powdered gloves are preferred because powders adsorb the drugs. Powdered latex gloves also adsorb latex proteins. Workers who use powdered latex gloves are exposed to more of the latex proteins that cause latex allergy in some persons. Workers who have developed an allergy to latex proteins must be provided with vinyl or nitrile gloves or glove liners.
Protective gown
A gown made of low permeability fabric with a closed front, long sleeves, and closed cuffs is recommended.
Eye protection
Eye protection, such as splash goggles, should be made available for use in any situation where there is a risk of splashes into the eyes. Eye protection should also be used when cleaning up spills.
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Use of personal protective equipment
• Gloves should be routinely changed approximately every hour or immediately if they are torn or punctured. Double gloving is recommended for cleaning up spills.
• Potentially contaminated gowns or gloves should not be worn outside the work area.
• Hands must be washed before and after gloving.
• If an accidental spill or splash occurs, contaminated clothing should be removed immediately and contaminated skin or eyes should be flushed immediately with copious amounts of running water to effectively cleanse the area.
Supplies and equipment for drug preparation, administration, and waste disposal
Suitable preparation, administration, and waste disposal supplies and equipment must be made available to the workers. These include:
• disposable, absorbent, plastic backed sheeting to cover the work area and potential leakage areas
• equipment to vent reconstituted vials to reduce internal pressure and potential for spillage or liquid spraying when a needle is withdrawn from the vial septum (e.g., a disposable needle and a 0.2 µm hydrophobic filter unit, such as the Millex Vial Vent Unit)
• syringes and intravenous sets with Luer-lock fittings
• disposal collection containers such as a plastic or metal tray lined with sterile gauze to collect excess solution
• closable, puncture-resistant, labelled containers for disposal of contaminated sharp or breakable materials
• labelled, sealable or wiretie plastic bags of sufficient thickness (4 mil thick polyethylene or 2 mil polypropylene) for the collection of waste including used gloves, paper liners, used disposable gowns, unused pills, powder residues and containers, and used gauze and alcohol wipes
• spill cleaning material including absorbent gauze pads, spill control pillows, and a small scoop to collect glass fragments
• sterile gauze pads to surround ampoules before breaking them open
Work procedures
Written safe work procedures or specific instructions are a part of the written plan. They should be formulated or otherwise adapted from existing written/published procedures. The employer must implement and train workers on the procedures and make them available to all personnel involved in the mixing and/or administration of the drugs. There are several written/published procedures availableSaskatchewan Cancer Agency Guidelines, the U.S. Occupational Health and Safety Administration Guidelines, Canadian Society of Hospital Pharmacists Guidelines, the American Pharmaceutical Society Guidelines, etc. One or more of these documents should be obtained and adapted to the workplace (See the Resources section).
Training
The employer must ensure workers are:
• informed of the hazards of cytotoxic drugs and risks of exposure
• instructed on proper precautions
• trained on safe work procedures
• supervised to make sure they follow safe work procedures Pre-job training must be given to all personnel involved in the mixing and/or administration of cytotoxic drugs.
The training must include housekeeping, laundry, and janitorial staff. They must receive training on the potential hazards of handling laundry, excreta, etc., contaminated with cytotoxic drugs, and safe work procedures when handling these materials. The training should be continually assessed and reinforced.
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The written program must address how training will be developed, delivered, and evaluated.
Additional protection for pregnant workers
A pregnant worker who may be exposed to hazardous amounts of cytotoxic drugs may notify the employer that she is pregnant. In this situation, the employer must minimize this worker's exposure (section 308 of the regulations). If this is not reasonably practicable, the employer must transfer a pregnant worker, on the worker's request, to duties that do not involve handling cytotoxic drugs, where such duties are available. • Bischloroethyl nitrosourea or carmustine (BiCNU)
Resources
• 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea or lomustine (CeeNU)
• Cisplatin (Platinol)
• Doxorubicin (Adriamycin)
• Nitrogen mustard (Mustargen)
• Procarbazine (Natulan)
• Methoxsalen, plus UV radiation (Oxsoralen, Oxsoralen-Ultra, UltraMOP)
Group 2B -Drugs which are possibly carcinogenic to humans (generally, limited human evidence, but absence of animal evidence) 6 • Bleomycin sulfate (Blenoxane)
• Dacarbazine (DTIC)
• Mitomycin (Mutamycin)
• Streptozocin (Zanosar)
• Daunorubicin (Cerubidine)
• Medroxyprogesterone acetate (Alti-MPA, Depo-Provera, Provera)-cancer, hormone Drugs with evidence of carcinogenicity which, at present, are not used clinically in Canada
• Chlornaphazine (Group 1)
• 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea or Methyl-CCNU (Group 1)
• Treosulphan (Group 1)
• Aminouracil mustard or Uracil mustard (Group 2B)
• Nitrogen mustard, n-oxide (Group 2B)
• Azacitidine (Group 2A)
• Chlorozotocin (Group 2A)
• Trichlormethine (Group 2B)
The Class II, Type A BSC A. front opening B. sash C. exhaust HEPA filter D. supply HEPA filter E. rear plenum F. blower An internal blower draws sufficient room air through the front grille to maintain a minimum calculated or measured average inflow velocity of at least 75 lfpm at the face opening of the cabinet. The supply air flows through a HEPA filter and provides particulate-free air to the work surface. Laminar airflow reduces turbulence in the work zone and minimizes the potential for cross-contamination. The downward moving air "splits" as it approaches the work surface; the blower draws part of the air to the front grille and the remainder to the rear grille. Although there are variations among different cabinets, this split generally occurs about halfway between the front and rear grilles, and two to six inches above the work surface. The air is then discharged through the rear plenum into the space between the supply and exhaust filters located at the top of the cabinet. Due to the relative size of these two filters, approximately 30 percent of the air passes through the exhaust HEPA filter and 70 percent recirculates through the supply HEPA filter back into the work zone. Most Class II, Type A cabinets have dampers to modulate this 30/70 division of airflow. An unducted Class II Type A BSC is not to be used for work involving volatile or toxic chemicals. The buildup of chemical vapors in the cabinet (by recirculated air) and in the laboratory (from exhaust air) could create health and safety hazards.
It is possible to duct the exhaust from a Type A cabinet out of the building. However, it must be done in a manner that does not alter the balance of the cabinet exhaust system, thereby disturbing the internal cabinet airflow. The typical method of ducting a Type A cabinet is to use a "thimble," or canopy hood, which maintains a small opening (usually one inch) around the cabinet exhaust filter housing. The volume of the exhaust must be sufficient to maintain the flow of room air into the space between the thimble unit and the filter housing (contact manufacturers for any additional specifications). The thimble must be removable or be designed to allow for operational testing of the cabinet. The performance of a cabinet with this exhaust configuration is unaffected by fluctuations in the building exhaust system.
Thimble unit for ducting a Class II, Type A BSC.
Note: There is a one inch gap between the thimble unit (D) and the exhaust filter housing (C), through which room air is exhausted. A. balancing damper B. flexible connect to exhaust system C. cabinet exhaust HEPA filter housing D. thimble unit E. BSC "Hard-ducting" (i.e., direct connection) of Class II Type A cabinets to the building exhaust system is not recommended. The building exhaust system must be precisely matched to the airflow from the cabinet in both volume and static pressure. However, fluctuations in air volume and pressure that are common to all building exhaust systems make it difficult, if not impossible, to match the airflow requirements of the cabinet.
The cabinet supply blowers draw room air (plus a portion of the cabinet's recirculated air) through the front grille and then through the supply HEPA filters located immediately below the work surface. This particulate-free air flows upward through a plenum at each side of the cabinet and then downward to the work area through a backpressure plate. In some cabinets there is an additional supply HEPA filter to remove particulates that may be generated by the blower/motor system. Room air is drawn through the face opening of the cabinet at a minimum inflow velocity of 100 lfpm. As with the Type A cabinet, there is a split in the down-flowing air stream just above the work surface. In the Type B cabinet, approximately 70 percent of the downflow air exits through the rear grille, passes through the exhaust HEPA filter, and is discharged from the building. The remaining 30 percent of the downflow air is drawn through the front grille. Since the air which flows to the rear grille is discharged into the exhaust system, activities that may generate hazardous chemical vapors or particulates should be conducted towards the rear of the cabinet Type Bl cabinets must be hard-ducted, preferably to their own dedicated exhaust system, or to a properly designed laboratory building exhaust. As indicated earlier, blowers on laboratory exhaust systems should be located at the terminal end of the duct work. A failure in the building exhaust system may not be apparent to the user, as the supply blowers in the cabinet will continue to operate. A pressure-independent monitor should be installed to sound an alarm and shut off the BSC supply fan should failure in exhaust airflow occur. Since this feature is not supplied by all cabinet manufacturers, it is prudent to install a sensor in the exhaust system as necessary. To maintain critical operations, laboratories using Type B BSCs should connect the exhaust blower to the emergency power supply.
presence of such an interlock system should be verified so systems can be retrofitted if necessary. Exhaust air movement should be monitored by a pressure-independent device.
